Recently Issued Guidance Documents
Should you find a Web link (URL) embedded within guidance documents that does not work or other documents posted on the FDA Web site, please try searching for the document using the document title. If you need further assistance, please go to Contact FDA.
-
Select Updates for the Premarket Cybersecurity Guidance: Section 524B of the FD&C Act; Draft Guidance for Industry and Food and Drug Administration Staff
CDRH/CBER, March 2024 -
Early Alzheimer’s Disease: Developing Drugs for Treatment; Draft Guidance for Industry
CDER/CBER, March 2024 -
Clinical Pharmacology Considerations for Antibody-Drug Conjugates; Guidance for Industry
CDER/CBER, March 2024 -
Key Information and Facilitating Understanding in Informed Consent; Draft Guidance for Sponsors, Investigators, and Institutional Review Boards
CDER/CBER/CDRH/OCLiP/OHRP, March 2024 -
Reporting Amount of Listed Drugs and Biological Products Technical Conformance Guide; Guidance for Industry
CDER/CBER/CVM, February 2024 -
Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment; Guidance for Industry
CDER/CBER, February 2024 -
Select Updates for the Medical Device User Fee Small Business Qualification and Certification Guidance; Draft Guidance for Industry and Food and Drug Administration Staff
CDRH/CBER, February 2024 -
Charging for Investigational Drugs Under an IND: Questions and Answers; Guidance for Industry
CDER/CBER/OCE, February 2024 -
Use of Data Monitoring Committees in Clinical Trials; Draft Guidance for Industry
CDER/CBER/CDRH, February 2024 -
Reporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the FD&C Act; Guidance for Industry
CDER/CBER/CVM, February 2024 -
Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&C Act; Draft Guidance for Industry
CDER/CBER, February 2024 -
Conducting Remote Regulatory Assessments Questions and Answers; Draft Guidance for Industry
ORA/OFPR/OCP/CBER/CDER/CDRH/OC/OCE/CFSAN/CTP/CVM, February 2024 -
Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products; Draft Guidance for Industry
CDER/CBER/CDRH/OC/OCE/OMHHE/OWH/OCLiP/OPT, January 2024 -
Human Gene Therapy Products Incorporating Human Genome Editing; Guidance for Industry
CBER, January 2024 -
Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products; Guidance for Industry
CBER, January 2024 -
Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile; Guidance for Industry and Food and Drug Administration Staff
CDRH/CBER, January 2024 -
Potency Assurance for Cellular and Gene Therapy Products; Draft Guidance for Industry
CBER, December 2023 -
Rare Diseases: Considerations for the Development of Drugs and Biological Products; Guidance for Industry
CDER/CBER, December 2023 -
Master Protocols for Drug and Biological Product Development; Draft Guidance for Industry
CDER/CBER, December 2023 -
Real-World Data: Assessing Registries To Support Regulatory Decision-Making for Drug and Biological Products; Guidance for Industry
CDER/CBER/OCE, December 2023 -
Digital Health Technologies for Remote Data Acquisition in Clinical Investigations; Guidance for Industry, Investigators, and Other Stakeholders
CDER/CBER/CDRH/OCE, December 2023 -
Data Standards for Drug and Biological Product Submissions Containing Real-World Data; Guidance for Industry
CDER/CBER, December 2023 -
Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices
CDRH/CBER, December 2023 -
Advanced Manufacturing Technologies Designation Program; Draft Guidance for Industry
CDER/CBER, December 2023 -
Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs; Guidance for Industry
CDER/CBER/ORA, December 2023 -
Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies; Guidance for Industry
CBER, October 2023 (Updated November 27, 2023) -
COVID-19: Developing Drugs and Biological Products for Treatment or Prevention; Guidance for Industry
CDER/CBER, November 2023 -
Translation of Good Laboratory Practice Study Reports: Questions and Answers; Draft Guidance for Industry
CDER/CBER/CDRH/CVM/CFSAN/CTP/ORA, November 2023 -
Notifying FDA of a Permanent Discontinuance or Interruption in Manufacturing of a Device Under Section 506J of the FD&C Act; Guidance for Industry and Food and Drug Administration Staff
CDRH/CBER, November 2023 -
Process to Request a Review of FDA's Decision Not to Issue Certain Export Certificates for Devices; Guidance for Industry and Food and Drug Administration Staff
CDRH/CBER, November 2023